EQRx, Inc. financial data

Symbol
EQRX, EQRXW on Nasdaq
Industry
Pharmaceutical Preparations
Location
50 Hampshire Street, Cambridge, Massachusetts
Fiscal year end
December 31
Former names
CM Life Sciences III Inc. (to 12/17/2021)

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.26K % -25.2%
Debt-to-equity 5.24 % -49.6%
Return On Equity -20.3 % -107%
Return On Assets -19.3 % -117%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 488M shares -0.15%
Common Stock, Shares, Outstanding 485M shares +1.78%
Entity Public Float 1.6B USD +181%
Common Stock, Value, Issued 49K USD 0%
Weighted Average Number of Shares Outstanding, Basic 484M shares +1.82%
Weighted Average Number of Shares Outstanding, Diluted 484M shares +1.82%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 206M USD -3.51%
General and Administrative Expense 101M USD -25.9%
Operating Income (Loss) -396M USD -13.1%
Nonoperating Income (Expense) 136M USD -33.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -169M USD -69.1%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -260M USD -78.7%
Earnings Per Share, Basic -0.54 USD/shares -80%
Earnings Per Share, Diluted -0.54 USD/shares -80%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 316M USD -68.4%
Cash, Cash Equivalents, and Short-term Investments 1.2B USD -20%
Assets, Current 1.24B USD -19%
Property, Plant and Equipment, Net 2.32M USD +52.8%
Operating Lease, Right-of-Use Asset 2.66M USD -45.6%
Other Assets, Noncurrent 1.15M USD -86.7%
Assets 1.24B USD -19.6%
Accounts Payable, Current 8.1M USD -42.4%
Accrued Liabilities, Current 55.6M USD +20.7%
Liabilities, Current 65.8M USD +4.99%
Operating Lease, Liability, Noncurrent 215K USD -91.9%
Liabilities 69.4M USD -51.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 252K USD
Retained Earnings (Accumulated Deficit) -766M USD -51.5%
Stockholders' Equity Attributable to Parent 1.17B USD -16.4%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 1.17B USD -16.4%
Liabilities and Equity 1.24B USD -19.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -85.5M USD -58.6%
Net Cash Provided by (Used in) Financing Activities 127K USD
Net Cash Provided by (Used in) Investing Activities -40.4M USD -310354%
Common Stock, Shares Authorized 1.25B shares 0%
Common Stock, Shares, Issued 538M shares -0.17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -126M USD -128%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 316M USD -68.3%
Deferred Tax Assets, Valuation Allowance 206M USD +73.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 207M USD +73.1%
Operating Lease, Liability 3.83M USD +13.5%
Depreciation 200K USD -33.3%
Payments to Acquire Property, Plant, and Equipment 444K USD +3315%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -258M USD -75.4%
Lessee, Operating Lease, Liability, to be Paid 4.09M USD +16%
Property, Plant and Equipment, Gross 3.76M USD
Operating Lease, Liability, Current 2.06M USD -17.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.5M USD +450%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.6M USD -20.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 260K USD +69.9%
Deferred Tax Assets, Operating Loss Carryforwards 86.6M USD +40.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 3.9M USD 0%
Additional Paid in Capital 1.94B USD +1.54%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 188K USD -54.1%
Deferred Tax Assets, Net of Valuation Allowance 1.62M USD +33.7%
Share-based Payment Arrangement, Expense 28.5M USD -48%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%